Cell Source

Cell Source EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Cell Source (CLCS) as of Oct 19, 2026 is -16.84. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -16.19 — a change of 3.98% (lower).

EV/OCF

-16.84

YoY

3.98%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Cell Source is 2025 -16.84 . EV/OCF (Enterprise Value to Operating Cash Flow) of Cell Source was 2024 -16.19 . It decreases by 3.98% lower compared to the previous year.

The Cell Source EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-18.04 USD
Jan 1, 2019
-13.93 USD
Jan 1, 2020
-13.71 USD
Jan 1, 2021
-11.79 USD
Jan 1, 2022
-10.66 USD
Jan 1, 2023
-18.19 USD
Jan 1, 2024
-16.19 USD
Jan 1, 2025
-16.84 USD
The Cell Source EV/OCF history
YEAREV/OCFYoY
-16.84+3.98%
-16.19-10.97%
-18.19+70.55%
-10.66-9.58%
-11.79-13.96%
-13.71-1.61%
-13.93-22.79%
-18.04+15.33%
-15.64-36.06%
-24.47+40.94%
-17.36+61.41%
-10.75—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Source Stock analysis

What does Cell Source do? Cell Source Inc., based in New York City, operates in the Health Care sector as a biotechnology company specializing in immunotherapy. The company, listed on 14 January 2014, focuses on developing Veto Cell technology, an immune tolerance biotechnology enabling selective immune response blocking. Its lead product targets allogeneic hematopoietic stem cell transplantation, supporting haploidentical transplants with mild conditioning. The pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and non-malignant disorders. The firm holds a wholly owned subsidiary, Cell Source Limited. Cell Source is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Source stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Cell Source is -16.84 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Cell Source changed from -16.19 to -16.84, representing a 3.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Cell Source since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Cell Source with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cell Source

All Key Metrics — Cell Source